Core Insights - Perspective Therapeutics, Inc. is focused on advancing its proprietary radiopharmaceutical technology to redefine cancer treatment and aims to share maturing clinical data across all programs in 2026 [2][18] Clinical Pipeline Updates - The company is conducting a multi-center open-label dose-finding study of [Pb]VMT-α-NET for patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors [3] - Updated interim data from the study presented at ASCO-GI 2026 showed that 76% of patients in a specific cohort were without progression and remained alive [7][8] - VMT-α-NET continues to demonstrate strong patient recruitment and is well-tolerated, with no reports of dose-limiting toxicities [6][7] - Clinical updates for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors are expected in mid to late 2026 [6] Manufacturing Infrastructure - The company is expanding its manufacturing capabilities by enhancing capacity at existing facilities and building out recently acquired sites [15] Upcoming Events - The CEO will present updates at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [17]